Biogen Reports 2016 Revenues of $11.4 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) Tops Q4 EPS by 8c; FY17 Rev Guidance Falls Below the Street
January 26, 2017 6:32 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $5.04, $0.08 better than the analyst estimate of $4.96. Revenue for the quarter came in at $2.87 billion versus the consensus estimate of $2.94 billion.
GUIDANCE:
Biogen sees FY2017 EPS of $20.45-$21.45, versus the consensus of $21.02. Biogen sees FY2017 revenue of $11.1-11.4 billion, versus the consensus of $12.07 billion.
"
Biogen seeks to advance transformational... More
